| |
Dual therapy
|
Triple therapy
|
P
|
|---|
|
N
|
%
|
N
|
%
|
|---|
|
Enrolled patients
|
72
|
28.9
|
177
|
71.1
| |
|
Female
|
28
|
38.9
|
39
|
22.0
|
0.007
|
|
Risk factor for HIV acquisition
|
|
Sexual
|
30
|
41.7
|
103
|
58.2
| |
|
Intravenous drug use
|
29
|
40.3
|
46
|
26.0
| |
|
Transfusion/vertical/unknown
|
13
|
5.6
|
28
|
1.1
|
0.04
|
|
Ethnicity
|
|
Caucasian
|
70
|
97.2
|
165
|
93.2
| |
|
Other
|
2
|
2.8
|
12
|
6.8
|
0.21
|
|
Naive
|
1
|
1.4
|
8
|
4.5
|
0.45
|
|
CDC stage
|
|
A
|
15
|
20.8
|
47
|
26.6
| |
|
B
|
40
|
55.6
|
68
|
38.4
| |
|
C
|
17
|
23.6
|
62
|
35.0
|
0.59*
|
|
HIVRNA > 50 copies/mL at T0**
|
11
|
15.5
|
12
|
7.1
|
0.04
|
|
Previous regimen including**
|
|
PI
|
61
|
85.9
|
161
|
95.3
|
0.01
|
|
NNRTI
|
15
|
21.1
|
4
|
2.4
|
< 0.0001
|
|
Hypercholesterolemia
|
44
|
61.1
|
77
|
43.5
|
0.03
|
|
Hypertriglyceridemia
|
11
|
15.3
|
30
|
16.9
|
0.67
|
| |
Mean or median
|
SD or IQR
|
Mean or median
|
SD or IQR
| |
|---|
|
Mean age, SD (years)
|
50.2
|
10.8
|
48.2
|
10.1
|
0.17
|
|
Mean CD4, SD (cells/mm3)
|
625
|
381
|
581
|
343
|
0.37
|
|
Median time on PI, IQR (years)
|
8.8
|
5.9–11.5
|
5.8
|
2.5–10.0
|
0.001
|
|
Median time on NNRTI, IQR (years)
|
2.4
|
0.9–4.8
|
1.6
|
0.1–5.3
|
0.12
|
|
Median time on ART, IQR (years)
|
18.1
|
7.8–21.0
|
9.0
|
3.2–17.9
|
< 0.0001
|
|
Mean eGFR, SD (mL/min)
|
94.2
|
20.3
|
96.3
|
23.6
|
0.50
|
- SD: Standard deviation; PI: protease inhibitors; NNRTI: non nucleoside reverse transcriptase inhibitors; IQR: interquartile range; eGFR: estimated glomerular filtration rate
- * Mantel–Haenszel Chi square test
- ** Experienced patients, n = 240
